Cite
Cost-Effectiveness of Non-Statin Lipid-Modifying Agents for Primary and Secondary Prevention of Cardiovascular Disease among Patients with Type 2 diabetes mellitus: A Systematic Review.
MLA
Abushanab, Dina, et al. “Cost-Effectiveness of Non-Statin Lipid-Modifying Agents for Primary and Secondary Prevention of Cardiovascular Disease among Patients with Type 2 Diabetes Mellitus: A Systematic Review.” Journal of Emergency Medicine, Trauma & Acute Care, vol. 2022, no. 1, Jan. 2022, pp. 1–2. EBSCOhost, https://doi.org/10.5339/jemtac.2022.qhc.38.
APA
Abushanab, D., Al-Badriyeh, D., Marquina, C., Bailey, C., Jaam, M., Liew, D., & Ademi, Z. (2022). Cost-Effectiveness of Non-Statin Lipid-Modifying Agents for Primary and Secondary Prevention of Cardiovascular Disease among Patients with Type 2 diabetes mellitus: A Systematic Review. Journal of Emergency Medicine, Trauma & Acute Care, 2022(1), 1–2. https://doi.org/10.5339/jemtac.2022.qhc.38
Chicago
Abushanab, Dina, Daoud Al-Badriyeh, Clara Marquina, Cate Bailey, Myriam Jaam, Danny Liew, and Zanfina Ademi. 2022. “Cost-Effectiveness of Non-Statin Lipid-Modifying Agents for Primary and Secondary Prevention of Cardiovascular Disease among Patients with Type 2 Diabetes Mellitus: A Systematic Review.” Journal of Emergency Medicine, Trauma & Acute Care 2022 (1): 1–2. doi:10.5339/jemtac.2022.qhc.38.